Precision oncology for KRASG12C-mutant colorectal cancer

Allele-specific inhibitors of KRAS(G12C) are approved in non-small-cell lung cancer. Herein, we discuss recent results from the phase I/II KRYSTAL-1 trial of adagrasib alone and in combination with cetuximab in patients with KRAS(G12C)-mutant metastatic colorectal cancer. The combination had promising efficacy and, if confirmed in later-phase trials, concomitant inhibition of EGFR and KRAS(G12C) will present a new paradigm in precision oncology.